Adjuvant Chemotherapy with Taxanes Does Not Cause Ovarian Failure or Osteopenia in an animal model
Osteologie · 2026-10-16
DOI: 10.1055/a-2935-4872 ↗Abstract
Abstract Cancer treatment-induced bone loss (CTIBL) is a recognised late complication in cancer survivors. The proposed mechanism links chemotherapy-induced ovarian failure and subsequent oestrogen deficiency to bone mineral density (BMD) reduction. Whether taxane-based chemotherapy independently impairs ovarian function and bone mass in hormonally competent animals has not been conclusively established. 50 female Sprague-Dawley rats (age 6 months) were allocated to three groups: SHAM/DOC (sham-ovx+6 cycles of docetaxel i. v. at 3-week intervals; n=15), OVX/Placebo (ovx+placebo; n=20), and SHAM/Placebo (sham-ovx+placebo; n=15). After a 12-week period, BMD of the lumbar vertebrae (L5) was measured by DXA (Hologic) before and 12 weeks after completion of chemotherapy. Ovarian function was assessed by vaginal cytology, serum oestradiol, and ovarian histology. OVX reliably induced secondary amenorrhoea, oestradiol suppression (5.99 ng/l vs. 16.85–21.11 ng/l in sham groups; p
EUVIMED